Naglazyme (Galsulfase)
Purpose of Medication and Method of Action
This is the first drug approved for the treatment of mucopolysaccharidosis VL (MPS VI). MPS VI is cause by a deficiency of the enzyme N-acetylgalactosamine 4-sulfatase which leads to an accumulation of glycosaminoglycans. The accumulation of glycosaminoglycans is believed to be responsible for the systemic effects of this disease. Naglazyme reduces the accumulation of the glycosaminoglycans and results in a significant improvement of symptoms of this disease in affected patients. Naglazyme restricted in availability in the USA to physicians and hospitals. A compassionate release program on a named patient basis is available for international patients.
Patient Medication Information
These information sheets do not list all known side effects of the medications, only the most common side effects. For a complete list of side effects please contact your local pharmacy or the actual drug manufacturing company.